Tamtam Try Tamtam free
ALK logo

ALK account plan

Long-term allergy treatment provider

At a glance

ALK-Abelló is a Danish allergy pharma company: immunotherapy tablets, injections and drops plus anaphylaxis products, DKK 6,312 million revenue in FY2025.

ALK-Abelló A/S, headquartered in Hørsholm, Denmark and listed on Nasdaq Copenhagen (ALK B), develops, produces and markets products to diagnose and treat allergies, allergic asthma and acute anaphylactic reactions. Its core is disease-modifying allergy immunotherapy (AIT) in tablet, injection (SCIT) and drop form, where it estimates a ~48% global market share, alongside the Jext® adrenaline autoinjector and the neffy® nasal adrenaline spray. In FY2025 revenue grew 15% in local currencies to DKK 6,312 million, EBIT rose 53% to DKK 1,654 million (26% margin) and net profit was DKK 1,197 million. ALK had 2,711 employees, 9 production sites in Europe and the USA, and serves 44 markets directly and through partners such as GenSci (China), Torii/Shionogi (Japan) and ARS Pharma. The Lundbeck Foundation is a major shareholder; 59.2% of the B shares are free float.

Business units

Strategic priorities

Allergy+ strategy to 2028
Help 5 million people with allergy a year by 2030 (3.1 million treated in 2025), with average organic revenue growth of at least 10% over 2023-2028, an EBIT margin around 25% and NIBD/EBITDA of at most two.
Paediatric tablet expansion
Roll out the house dust mite and tree tablets to children and reach paediatricians and ENT specialists as new prescriber groups; more than 4,000 prescribers in directly served markets had prescribed one of the two to children by end-2025.
Make neffy® a success
Launch EURneffy® in up to 15 European markets in 2026 and co-promote neffy® in the USA to ~9,000 paediatricians with a dedicated 65-rep sales force shared with ARS Pharma.
Grow North America
Grow North America by more than 10% a year towards 2028 by working beyond allergists, educating prescribers and payers, and preparing the peanut tablet launch.
Food allergy pipeline
Advance the peanut SLIT tablet (FDA Fast Track; phase 3 clinical trial application submitted), a tree nut tablet and the ALK014 biologic, which is progressing toward clinical development in 2027.
Tablet capacity and digitalisation
Upscale tablet production capacity to 800 million units a year by 2030 within the existing footprint, and invest in digitalisation and AI among the 2026 priorities.

Latest results

In Q3 2026 revenue rose 15% in local currencies to DKK 1,764 million (1,530) and EBIT rose 9% to DKK 469 million, a 27% margin (28%). Tablets grew 35% while SCIT/SLIT drops fell 6% on lower China shipments. Over the first nine months of 2026 revenue was DKK 5,330 million (+17%), EBIT DKK 1,484 million (+16%, 28% margin), net profit DKK 1,138 million and free cash flow DKK 1,192 million (836). Capacity costs rose 20%, with R&D up 24% and sales and marketing up 20% on paediatric tablet and neffy® launches. The full-year 2026 outlook, upgraded on 7 October, was confirmed: revenue growth of 16-17% in local currencies, an EBIT margin around 27% and free cash flow slightly above DKK 1,100 million.

Investments and deals

Catalent tablet supply agreement
Expanded in 2026: long-term access to the Zydis® formulation and tablet capacity of 1.1 billion a year from the early 2030s, for around half a billion DKK over 3 years.
GenSci partnership in China
DKK 244 million upfront, with ~DKK 300 million regulatory and up to ~DKK 780 million commercial milestones until 2039; the ACARIZAX® phase 3 bridging trial met its primary objective, with filing expected in H1 2027 and a possible launch late 2028.
ARS Pharma neffy® licence
About USD 145 million upfront for neffy® rights in most markets outside the US, plus US co-promotion in paediatrics; a DKK 32 million milestone was paid in 2025.
2026 capex
Capex around DKK 400 million plus up to DKK 100 million under the Catalent agreement; ALK says its financial position lets it look increasingly at in-licensing and acquisitions.
Partnerships for new markets and research
Zuellig Pharma will sub-license neffy® in six Southeast Asian markets; a seed partnership with Allegria Therapeutics gives rights to negotiate in-licensing of up to three targets.

Challenges and risks

Pricing and reimbursement pressure
Market acceptance and authority-mandated price pressure are flagged as increasing risks; ALK is executing an action plan against Germany's mandatory rebate increase from 1 January 2027, and Germany is 25% of revenue.
Structure of the US allergy market
The US market grew around allergists compounding their own extracts, which the CEO says keeps North America closer to one fifth of revenue; the annual report cites allergists with a financial incentive to protect their legacy business.
Product development risk
Failures or delays in product development are flagged as an increasing risk; the peanut tablet phase 3 awaits FDA feedback on the clinical trial application.
Supply and third-party dependence
Production and quality issues and dependence on key third parties, notably for tablets, are among the main enterprise risks; SCIT initiations in Germany and the Nordics were limited by allergy-clinic capacity.
Rising capacity costs
Capacity costs rose 20% over the first nine months of 2026, and gross margin is expected to come under slight pressure as partner-related sales grow.

What leadership says

“ALK's 35% tablet growth in Q3 reflects the strength of our strategy, and paediatric use is increasingly contributing to the growth.”

Peter Halling, President & CEO · Nine-month interim report (Q3) 2026, 17 November 2026

“The constraint has not been demand, but the way the system itself evolved.”

Peter Halling, President & CEO · PharmaBoardroom interview on the US market and Allergy+, 21 January 2026

“The objective is not to replace existing approaches, but to complement them and expand overall treatment capacity.”

Peter Halling, President & CEO · PharmaBoardroom interview on the US market and Allergy+, 21 January 2026

“ALK is not a turnaround case, we are an established, successful company”

Peter Halling, President & CEO · PharmaBoardroom interview on Allergy+ strategy and leadership, 27 May 2025

Where a supplier can help

Launch support for paediatric tablets and neffy®
The paediatric tablet roll-out and EURneffy® launches in up to 15 European markets need prescriber targeting, medical education and field-force tools aimed at paediatricians and ENT specialists.
US market access and payer work
The North America growth target depends on navigating insurers, PBMs and state-level variation and on educating prescribers beyond allergists, where market access and commercial analytics partners can help.
Tablet manufacturing scale-up
The capacity target of 800 million units a year by 2030 and the Catalent expansion create needs in production equipment, quality systems and supply-chain planning.
Cost control against rebates
With capacity costs up 20% and Germany's rebate increase from 2027, suppliers offering efficiency in commercial operations, procurement or the digitalisation and AI priority have a clear entry point.
Clinical development services
The peanut tablet phase 3, largely in the US and Canada, and ALK014 moving to the clinic in 2027 point to needs for CRO, regulatory and trial-recruitment support.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like ALK?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about ALK

What does ALK do?

ALK-Abelló is a Danish pharmaceutical company focused on allergy. It sells disease-modifying allergy immunotherapy as tablets, injections and drops, and anaphylaxis products such as the Jext® autoinjector and the neffy® nasal adrenaline spray.

What is ALK's revenue?

FY2025 revenue was DKK 6,312 million, up 15% in local currencies, with EBIT of DKK 1,654 million. For 2026 ALK guides revenue growth of 16-17% in local currencies and an EBIT margin around 27%.

How many employees does ALK have?

ALK had 2,711 employees at end-2025: 2,161 in Europe, 533 in North America and 17 in International markets.

What is ALK's strategy?

Under Allergy+ ALK aims to help 5 million people a year by 2030, growing organically by at least 10% a year on average over 2023-2028 at an EBIT margin around 25%, driven by paediatric tablets, neffy® and a food allergy pipeline.

Who leads ALK?

Peter Halling is President & CEO, with Claus Steensen Sølje as EVP & CFO and Henriette Mersebach as EVP R&D. The board is chaired by Anders Hedegaard.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)